These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 29791078)

  • 41. FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
    Fan EW; Li CC; Wu WJ; Huang CN; Li WM; Ke HL; Yeh HC; Wu TF; Liang PI; Ma LJ; Li CF
    J Urol; 2015 Jul; 194(1):223-9. PubMed ID: 25623741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors.
    Gylling AH; Nieminen TT; Abdel-Rahman WM; Nuorva K; Juhola M; Joensuu EI; Järvinen HJ; Mecklin JP; Aarnio M; Peltomäki PT
    Carcinogenesis; 2008 Jul; 29(7):1351-9. PubMed ID: 18550572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
    Yates DR; Catto JW
    World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (hereditary nonpolyposis colorectal cancer syndrome).
    Hubosky SG; Boman BM; Charles S; Bibbo M; Bagley DH
    BJU Int; 2013 Oct; 112(6):813-9. PubMed ID: 23452166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance.
    Pradere B; Lotan Y; Roupret M
    Curr Opin Urol; 2017 Jan; 27(1):48-55. PubMed ID: 27533503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma.
    Kobayashi G; Hayashi T; Sentani K; Ikeda K; Babasaki T; Shigematsu Y; Sekino Y; Uraoka N; Teishima J; Matsubara A; Hinata N; Oue N
    Pathobiology; 2023; 90(2):94-103. PubMed ID: 35780773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?
    Krabbe LM; Lotan Y; Bagrodia A; Gayed BA; Darwish OM; Youssef RF; Bolenz C; Sagalowsky AI; Raj GV; Shariat SF; Kapur P; Margulis V
    J Urol; 2014 Apr; 191(4):926-31. PubMed ID: 24060642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
    Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
    Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrent Papillary Bladder Tumors in a Boy With Lynch Syndrome.
    Tua-Caraccia R; Livingston A; Routh JC
    Urology; 2023 Nov; 181():133-135. PubMed ID: 37422136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome.
    Dominguez-Valentin M; Joost P; Therkildsen C; Jonsson M; Rambech E; Nilbert M
    BMC Urol; 2016 Mar; 16():15. PubMed ID: 27013479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.
    David KA; Mallin K; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    Cancer; 2009 Apr; 115(7):1435-47. PubMed ID: 19215030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma.
    Lonati C; Moschini M; Simeone C; Spiess PE; Necchi A
    Curr Opin Urol; 2022 Jan; 32(1):40-47. PubMed ID: 34608026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
    J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison.
    Sanford T; Porten S; Meng MV
    PLoS One; 2015; 10(8):e0137141. PubMed ID: 26317352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location.
    Zigeuner RE; Hutterer G; Chromecki T; Rehak P; Langner C
    BJU Int; 2006 Dec; 98(6):1181-6. PubMed ID: 17125475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High Consumption of Green Tea Suppresses Urinary Tract Recurrence of Urothelial Cancer
    Yasuda T; Miyata Y; Nakamura Y; Sagara Y; Matsuo T; Ohba K; Sakai H
    In Vivo; 2018; 32(4):721-729. PubMed ID: 29936451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mononucleotide precedes dinucleotide repeat instability during colorectal tumour development in Lynch syndrome patients.
    Ferreira AM; Westers H; Sousa S; Wu Y; Niessen RC; Olderode-Berends M; van der Sluis T; Reuvekamp PT; Seruca R; Kleibeuker JH; Hollema H; Sijmons RH; Hofstra RM
    J Pathol; 2009 Sep; 219(1):96-102. PubMed ID: 19521971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma.
    Wang Y; Zhang J; Wang Y; Wang S; Zhang Y; Miao Q; Gao F; He H
    Front Med; 2019 Dec; 13(6):730-740. PubMed ID: 31020542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.